secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009649
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports $2.1M KOMZIFTI net revenue in first 5 weeks post-launch; cash at $667M
--------------------------------------------------------------------------------

- $2.1M KOMZIFTI net product revenue from Nov 21 to Dec 31, 2025 (first commercial sales).
- $195M milestone payment from Kyowa Kirin in Q4 2025; non-cash collaboration revenue $15-17M.
- Cash, cash equivalents & short-term investments $667.3M as of Dec 31, 2025.
- KOMZIFTI granted full FDA approval in Nov 2025 for R/R NPM1-mutated AML; NCCN Category 2A.
- 2026 guidance: non-cash collaboration revenue $45-55M; pipeline milestones include Phase 3 trial enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526009649/0001193125-26-009649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526009649/d55582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer